Feature | Drug-Eluting Balloons | October 22, 2015

Scoring Balloon Plus Drug-Coated Balloon Proves Effective for Drug-Eluting Stent Restenosis

Results of the ISAR-DESIRE 4 trial, presented at TCT 2015, show improved plaque modification versus DCB alone

ISAR-DESIRE 4 trial, TCT 2015, drug-coated balloon, DCB, scoring balloon, SCB, drug-eluting stent restenosis

Image courtesy of Medtronic

October 22, 2015 — Results from the ISAR-DESIRE 4 trial indicate that use of a scoring balloon plus a paclitaxel-coated balloon (PCB) was angiographically superior to a paclitaxel-coated balloon alone for the treatment of restenosis within limus-eluting stents.

Findings from the study were presented last week at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

Restenosis after drug-eluting stent implantation (DES) in patients with coronary artery disease occurs in up to 5-10 percent of cases, and the most appropriate treatment strategy remains unclear. Drug-coated balloons (DCB) are novel devices that can effectively treat in-stent restenosis. Scoring balloon (SCB) devices prevent balloon slippage and enhance local plaque disruption during angioplasty but have failed to demonstrate an advantage when used as stand-alone therapy. As an adjunct to DCB, scoring balloon pre-dilatation might enhance tissue uptake and improve clinical outcomes. ISAR-DESIRE 4 examined if the addition of a scoring balloon would lead to better results.

A prospective, randomized, active controlled, multicenter clinical trial, ISAR-DESIRE 4 enrolled 252 patients with limus-eluting stent restenosis and signs of ischemia. Patients were randomized 1:1 to a scoring balloon plus paclitaxel-coated balloon (N=125) or standard balloon plus paclitaxel-coated balloon (N=127) during angioplasty. Angiographic follow-up at six to eight months was performed in 80.4 percent of patients (N=203) and clinical follow-up occurred at 12 months.

The primary endpoint was the percent diameter stenosis at follow-up angiography. The results were 40.4 percent ± 21.4 for the SCB plus PCB group vs. 35 percent ± 16.8 for the PCB-alone group (p=0.047). The secondary endpoint of binary restenosis was also lower in SCB plus PCB compared to PCB alone (18.5 percent vs. 32 percent, P=0.03). The rates of target lesion revascularization (16.8 percent vs. 22.6 percent, P=0.25) and death/myocardial infarction (3.4 percent vs. 3.3 percent, P>0.99) were similar for both groups. 

“In patients with limus-eluting stent in-stent restenosis, plaque modification with SCB plus PCB was angiographically superior to standard PCB therapy in terms of in-segment percent diameter stenosis after six to eight month follow-up,” said investigator Robert A. Byrne, MB, B.Ch., Ph.D. from Deutsches Herzzentrum in Munich, Germany.

“Even though the rate of binary restenosis was lower with SCB plus PCB, clinical outcomes at one year were similar for both groups.”

The ISAR-DESIRE 4 trial was supported in part by a research grant from Biotronik AG. Byrne reported receiving lecture fees from B. Braun Melsungen AG, Biotronik and Boston Scientific.

For more information: www.tctconference.com

Related Content

Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020

Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip was the subject of two studies, including use to aid heart transplant patients. Bottom right, the Boston Scientific Acurate neo TAVR valve performed below the Sapien 3 and CoreValve Evolut.

Feature | TCT | October 29, 2020 | Dave Fornell, Editor
Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials prese
TCT 2020 Late-breaking Study trial Presentations Announced. #TCTconnect #TCT2020 #TCT
Feature | TCT | October 29, 2020
October 29, 2020 — The late-breaking studies are one of the hallmarks of the annual...
Interventional cardiology and structural heart pioneer Martin Leon, M.D., is the name-sake of the new joint ACC-CRF Center for Cardiovascular Transformation. 

Interventional cardiology and structural heart pioneer Martin Leon, M.D., is the name-sake of the new joint ACC-CRF Center for Cardiovascular Transformation. 

News | TCT | October 14, 2020
October 14, 2020 — The American College of Cardiology (ACC) and the...
Videos | TCT | August 01, 2020
With COVID-19 forcing all medical conferences to go virtual in 2020,...
EchoPixel showed technology at TCT 2019 that creates live holograms in the cath lab from 3-D TEE imaging. It projects the holograms on a special display screen that does not require the user to wear 3-D glasses. The interventional cardiologist can use hand movements and a foot switch to move the image around without breaking the sterile field. It offers a new way to visualize catheters, device positioning and deployment for structural heart procedures. #TCT2019 #TCT #TCT19

EchoPixel showed technology at TCT 2019 that creates live holograms in the cath lab from 3-D TEE imaging. It projects the holograms on a special display screen that does not require the user to wear 3-D glasses. The interventional cardiologist can use hand movements and a foot switch to move the image around without breaking the sterile field. It offers a new way to visualize catheters, device positioning and deployment in structural heart procedures. (Photos by Dave Fornell)

Feature | TCT | November 04, 2019 | Dave Fornell, Editor
The latest in interventional cardiology clinical data and new device technologies were highlighted at the annual ...
TCT 2019 Late-breaking Presentations in the main arena. The top interventional cardiology studies of 2019. #TCT #TCT19 #TCT2019
Feature | TCT | October 11, 2019
The Cardiovascular Research Foundation (CRF) has announced the 12 late-breaking trials and 16 late-breaking science...
Videos | TCT | October 03, 2018
DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the ex
cardiologist Ted Feldman, M.D., at TCT 2017. #TCT2018 #TCT #TCT18 TCT Late breaking trials, studies.
Feature | TCT | September 21, 2018
October 4, 2018 – The Cardiovascular Research Foundation (CRF) had 15 late-breaking trials and 12 late-breaking clini
Interventional cardiology, cath lab technology, TCT, transcatheter cardiovascular therapeutics. #TCT #TCT18 #TCT2018
Feature | TCT | September 14, 2018 | Dave Fornell, Editor
The volume of information attendees receive at the annual...